Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 5 studies | 23% ± 3% | |
glutamatergic neuron | 3 studies | 31% ± 6% | |
erythroblast | 3 studies | 32% ± 10% |
Insufficient scRNA-seq data for expression of TTLL12 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 3412.67 | 245 / 245 | 100% | 108.77 | 501 / 502 |
esophagus | 100% | 7142.97 | 1438 / 1445 | 99% | 111.96 | 182 / 183 |
uterus | 100% | 2658.44 | 170 / 170 | 99% | 78.40 | 454 / 459 |
intestine | 99% | 3054.93 | 961 / 966 | 99% | 91.84 | 523 / 527 |
stomach | 100% | 3227.53 | 358 / 359 | 99% | 84.21 | 283 / 286 |
bladder | 100% | 2641.62 | 21 / 21 | 98% | 66.84 | 495 / 504 |
breast | 99% | 2496.45 | 456 / 459 | 99% | 90.00 | 1104 / 1118 |
skin | 100% | 5666.88 | 1808 / 1809 | 97% | 70.31 | 459 / 472 |
ovary | 100% | 4278.63 | 180 / 180 | 97% | 48.83 | 415 / 430 |
pancreas | 98% | 2013.67 | 322 / 328 | 98% | 61.27 | 175 / 178 |
brain | 97% | 2754.41 | 2570 / 2642 | 98% | 44.52 | 689 / 705 |
lung | 95% | 1828.43 | 549 / 578 | 97% | 74.61 | 1120 / 1155 |
liver | 100% | 2413.28 | 225 / 226 | 91% | 34.19 | 369 / 406 |
kidney | 98% | 1640.13 | 87 / 89 | 84% | 24.72 | 756 / 901 |
thymus | 99% | 1904.58 | 649 / 653 | 80% | 23.50 | 481 / 605 |
adrenal gland | 100% | 5119.63 | 258 / 258 | 71% | 34.84 | 164 / 230 |
eye | 0% | 0 | 0 / 0 | 100% | 81.64 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 50.39 | 29 / 29 |
spleen | 100% | 2107.36 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 108.24 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 43.38 | 1 / 1 |
adipose | 100% | 2286.31 | 1198 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 1992.85 | 1321 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 83% | 2252.66 | 773 / 929 | 0% | 0 | 0 / 0 |
heart | 79% | 976.81 | 681 / 861 | 0% | 0 | 0 / 0 |
muscle | 76% | 1126.13 | 614 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0060339 | Biological process | negative regulation of type I interferon-mediated signaling pathway |
GO_0036211 | Biological process | protein modification process |
GO_0007346 | Biological process | regulation of mitotic cell cycle |
GO_0045087 | Biological process | innate immune response |
GO_0005813 | Cellular component | centrosome |
GO_0030496 | Cellular component | midbody |
GO_0005829 | Cellular component | cytosol |
GO_0005886 | Cellular component | plasma membrane |
GO_0005819 | Cellular component | spindle |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_1990889 | Molecular function | H4K20me3 modified histone binding |
GO_0005524 | Molecular function | ATP binding |
GO_0140943 | Molecular function | histone H4K20 trimethyltransferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0004835 | Molecular function | tubulin-tyrosine ligase activity |
GO_0015631 | Molecular function | tubulin binding |
Gene name | TTLL12 |
Protein name | Tubulin tyrosine ligase like 12 Tubulin--tyrosine ligase-like protein 12 (Inactive tubulin--tyrosine ligase-like protein 12) |
Synonyms | KIAA0153 |
Description | FUNCTION: Negatively regulates post-translational modifications of tubulin, including detyrosination of the C-terminus and polyglutamylation of glutamate residues . Also, indirectly promotes histone H4 trimethylation at 'Lys-20' (H4K20me3) . Probably by controlling tubulin and/or histone H4 post-translational modifications, plays a role in mitosis and in maintaining chromosome number stability . During RNA virus-mediated infection, acts as a negative regulator of the RIG-I pathway by preventing MAVS binding to TBK1 and IKBKE . . |
Accessions | V9GY16 ENST00000494035.1 Q14166 ENST00000216129.7 |